Abstract
Objectives Excess mortality captures the total effect of the COVID-19 pandemic on mortality and is not affected by mis-specification of cause of death. We aimed to describe how health and demographic factors have been associated with excess mortality during the pandemic.
Design Time-series analysis.
Setting UK primary care data from practices contributing to the Clinical Practice Research Datalink on July 31st 2020.
Participants We constructed a time-series dataset including 9,635,613 adults (≥40 years old) who were actively registered at the general practice during the study period.
Main outcome measures We extracted weekly numbers of deaths between March 2015 and July 2020, stratified by individual-level factors. Excess mortality during wave 1 of the UK pandemic (5th March to 27th May 2020) compared to pre-pandemic was estimated using seasonally adjusted negative binomial regression models. Relative rates of death for a range of factors were estimated before and during wave 1 by including interaction terms.
Results All-cause mortality increased by 43% (95% CI 40%-47%) during wave 1 compared with pre-pandemic. Changes to the relative rate of death associated with most socio-demographic and clinical characteristics were small during wave 1 compared with pre-pandemic. However, the mortality rate associated with dementia markedly increased (RR for dementia vs no dementia pre-pandemic: 3.5, 95% CI 3.4-3.5; RR during wave 1: 5.1, 4.87-5.28); a similar pattern was seen for learning disabilities (RR pre-pandemic: 3.6, 3.4-3.5; during wave 1: 4.8, 4.4-5.3), for Black or South Asian ethnicity compared to white, and for London compared to other regions.
Conclusions The first UK COVID-19 wave appeared to amplify baseline mortality risk by a relatively constant factor for most population subgroups. However disproportionate increases in mortality were seen for those with dementia, learning disabilities, non-white ethnicity, or living in London.
What is already known on this topic
All-cause mortality during the COVID-19 pandemic was higher than in previous years; this excess mortality was particularly pronounced among elderly people, males, people of non-white ethnicity, people of lower socio-economic status and people living in care-homes.
Several other papers have studied a wider range of factors associated with mortality due to COVID-19 using cause-of-death data.
There is little evidence on how all-cause mortality has changed in people with comorbidities.
What this study adds
Our study shows that during Wave 1 of the pandemic all cause death rates increased by a similar proportional degree for almost all population subgroups regardless of their health or socio-demographic circumstances; the exceptions were those with a diagnosis of dementia or learning disabilities and those of non-white ethnicity or living in London.
This suggests that COVID-19 has dialled up the risk of death by a similar proportional degree for everyone except those exposed to a higher risk of infection.
Competing Interest Statement
DL provides expert advice to Legal & General through his membership of their scientific panel on longevity. HS, HC, BDS and KB have no interests to declare.
Funding Statement
KB holds a Wellcome Senior Research Fellowship (220283/Z/20/Z) and also held a Sir Henry Dale fellowship (107731/Z/15/Z jointly funded by the Wellcome Trust and the Royal Society) during this study. This supported HS, HC and KB’s contribution to this study. DAL’s contribution was partly supported by the Basic Research Program of the National Research University Higher School of Economics.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the London School of Hygiene & Tropical Medicine Ethics Committee (22680) and the Independent Scientific Advisory Committee for the Medicines and Healthcare products Regulatory Agency database research (20_163R).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* joint first authors
H Strongman, Assistant Professor, helen.strongman{at}lshtm.ac.uk
H Carreira, Research Fellow, helena.carreira{at}lshtm.ac.uk
K Bhaskaran, Professor, krishnan.bhaskaran{at}lshtm.ac.uk
D A Leon, Professor, david.leon{at}lshtm.ac.uk
B L De Stavola, Professor, b.destavola{at}ucl.ac.uk
Data Availability
Individual patient data will not be available. The protocol is available in the supplementary appendix (p2-21) and all code lists are provide at https://doi.org/10.17037/DATA.00002269. All analytical code is available upon request to the corresponding author.
